UroEdge™

Imaging

Cancer diagnosis and therapy is becoming more focused toward a patient-specific approach to therapy, particularly prostate cancer. The role of imaging is paramount in this evolution by providing physicians with accurate information on both the presence and extent of prostate cancers. Developments in molecular imaging are paving the way for more physicians to diagnose cancer and apply relevant therapy. Various imaging modalities and methods may be best suited for different phases of the disease. Our associated physicians discuss the importance of imaging in more detail below.

PET Tumor Board

PET Tumor Board – Case 1: A Case of a 55-year-old Prostate Cancer Survivor with Rising PSA Five Years After Radical Prostatectomy

E. David Crawford, MD, presents a case of a 55-year-old prostate cancer survivor with rising PSA five years after radical prostatectomy.

PET Tumor Board Case 6: Patient with a Strong Family History of PCa

Three experts in urologic oncology join E. David Crawford, MD, to discuss a challenging prostate cancer case study.

PET Tumor Board Case 5: Gleason Grade 2 PCa After Multiple Treatments for BPH

Three experts in urologic oncology join E. David Crawford, MD, to discuss a challenging prostate cancer case study.

PET Tumor Board Case 4: Rapid Rise in PSA

Three experts in urologic oncology join E. David Crawford, MD, to discuss a challenging prostate cancer case study.

PET Tumor Board Case 3: Failing ADT and Proton Therapy

Three experts in molecular targeted imaging and oncology rejoin E. David Crawford, MD, to discuss a challenging prostate cancer case study.

PET Tumor Board Case 2: GRU Trilogy

Three experts in molecular targeted imaging and oncology rejoin E. David Crawford, MD, to discuss a challenging prostate cancer case study.

GRU PET Tumor Board Case 1: GRU Trilogy

Three experts in molecular targeted imaging and oncology join E. David Crawford, MD, to discuss a challenging prostate cancer case study.

Supported in part by Blue Earth Diagnostics, Inc.